Compare TISI & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TISI | ACRV |
|---|---|---|
| Founded | 1973 | 2018 |
| Country | United States | United States |
| Employees | 6800 | N/A |
| Industry | Other Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.5M | 82.2M |
| IPO Year | 1995 | 2022 |
| Metric | TISI | ACRV |
|---|---|---|
| Price | $16.34 | $1.38 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 12.1K | ★ 402.8K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.13 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $896,483,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $568.17 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.19 | N/A |
| 52 Week Low | $12.34 | $1.15 |
| 52 Week High | $20.79 | $3.56 |
| Indicator | TISI | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 49.86 | 30.33 |
| Support Level | $13.12 | $1.29 |
| Resistance Level | $16.62 | $2.22 |
| Average True Range (ATR) | 0.99 | 0.10 |
| MACD | 0.12 | -0.03 |
| Stochastic Oscillator | 40.59 | 1.90 |
Team Inc provides specialty industrial services, including inspection, engineering assessment, and mechanical repair and remediation required in maintaining high-temperature and high-pressure piping systems and vessels utilized in refining, petrochemicals, and others. The company operates in two segments, Inspection and Heat Treating and Mechanical Services. The Inspection and Heat Treating segment, which generates maximum revenue, provides conventional and non-destructive testing services for the process, pipeline, and power sectors, pipeline integrity management services, and field heat treating services, as well as associated engineering and condition assessment services. Geographically, the company derives its key revenue from the United States, followed by other countries, and Canada.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.